Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis

Clinical Benefit of Antiviral Agents for Hepatocellular Carcinoma Patients With Low Preoperative HBV-DNA Loads Undergoing Curative Resection: A Meta-Analysis

Background and AimsThe clinical benefit of adjuvant antiviral therapy after curative therapy for HCC in patients with high preoperative HBV-DNA loads has been studied widely but that in patients with low preoperative HBV-DNA loads remains controversial. The purpose of this study was to determine the...

Full description

Bibliographic Details
Main Authors: Kai-Xuan Liu, Jian-Guo Hong, Rui Wu, Zhao-Ru Dong, Ya-Fei Yang, Yu-Chuan Yan, Chun-Cheng Yang, Lun-Jie Yan, Sheng-Yu Yao, Hai-Chao Li, Xu-Ting Zhi, Tao Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
hepatocellular carcinoma
HBV reactivation
antiviral therapy
prognosis
HBV-DNA load
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.605648/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.605648/full

Similar Items